MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data by Shen, Shihao et al.
MATS: a Bayesian framework for flexible
detection of differential alternative splicing
from RNA-Seq data
Shihao Shen
1, Juw Won Park
2, Jian Huang
3, Kimberly A. Dittmar
4, Zhi-xiang Lu
2,
Qing Zhou
5, Russ P. Carstens
4,6 and Yi Xing
2,7,*
1Department of Biostatistics,
2Department of Internal Medicine,
3Department of Statistics and Actuarial Science,
University of Iowa, Iowa City, IA 52242,
4Renal Division, Department of Medicine, University of Pennsylvania,
School of Medicine, Philadelphia, PA 19104,
5Department of Statistics, University of California, Los Angeles, CA
90095, USA,
6Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104
and
7Department of Biomedical Engineering, University of Iowa, Iowa City, IA 52242
Received August 6, 2011; Revised December 10, 2011; Accepted December 15, 2011
ABSTRACT
Ultra-deep RNA sequencing has become a powerful
approach for genome-wide analysis of pre-mRNA
alternative splicing. We develop MATS (multivariate
analysis of transcript splicing), a Bayesian statistical
framework for flexible hypothesis testing of differ-
ential alternative splicing patterns on RNA-Seq data.
MATS uses a multivariate uniform prior to model
the between-sample correlation in exon splicing
patterns, and a Markov chain Monte Carlo (MCMC)
method coupled with a simulation-based adaptive
sampling procedure to calculate the P-value and
false discovery rate (FDR) of differential alternative
splicing. Importantly, the MATS approach is applic-
able to almost any type of null hypotheses of
interest, providing the flexibility to identify differen-
tial alternative splicing events that match a given
user-defined pattern. We evaluated the perform-
ance of MATS using simulated and real RNA-Seq
data sets. In the RNA-Seq analysis of alternative
splicing events regulated by the epithelial-specific
splicing factor ESRP1, we obtained a high RT–PCR
validation rate of 86% for differential exon skipping
events with a MATS FDR of <10%. Additionally,
over the full list of RT–PCR tested exons, the
MATS FDR estimates matched well with the experi-
mental validation rate. Our results demonstrate
that MATS is an effective and flexible approach for
detecting differential alternative splicing from
RNA-Seq data.
INTRODUCTION
Alternative splicing plays critical roles in regulating gene
function and activity in higher eukaryotes (1). By alterna-
tive selection of exons and splice sites during splicing, a
single gene locus can produce multiple mRNA and protein
isoforms with divergent structural and functional pro-
perties (2). Over 90% of multi-exon human genes are
alternatively spliced and many genes undergo changes in
alternative splicing during development, cell differenti-
ation and disease (3–6). Changes in alternative splicing
patterns can be manifested as all-or-none switches between
distinct mRNA isoforms, but more frequently as shifts in
the relative abundance of multiple mRNA isoforms of a
gene. In some disease genes, a slight shift (by as few as
several percent) in the relative isoform proportions can
trigger disease pathogenesis (7,8). Due to the prevalent
role of alternative splicing in gene regulation and disease,
there is a pressing need for genomic tools that can accur-
ately quantify isoform ratios and reliably detect changes in
isoform ratios (i.e. differential alternative splicing) among
different biological conditions.
Direct sequencing of full-length mRNAs and mRNA
fragments has been a popular and effective approach for
discovery and quantiﬁcation of alternative splicing events
(3,4,9). Since mRNAs represent the end products of
splicing, by aligning mRNA sequences to the genome
one can delineate exon–intron structures and identify al-
ternative splicing events. If sequencing reaches the sufﬁ-
cient depth, such that the relative abundance of distinct
mRNA isoforms can be conﬁdently estimated by the
numbers of RNA sequences matching to speciﬁc isoforms,
we can compare the mRNA sequence counts across bio-
logical conditions to identify differential alternative
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discovery of tissue-speciﬁc exons from expressed sequence
tags (ESTs) (10). Xu et al. categorized the ESTs of human
genes according to their tissue origins. The exon inclusion
level of an alternatively spliced cassette exon in any given
tissue was estimated from the counts of ESTs mapped
uniquely to the exon inclusion or skipping exon-exon junc-
tions (10) (for a formal deﬁnition, see ‘Materials and
Methods’ section). Using a Bayesian approach, Xu et al.
compared the EST counts across different tissues to detect
exons with tissue-speciﬁc shifts in exon inclusion levels.
Speciﬁcally, the prior distribution of an exon’s exon inclu-
sion levels in two tissues was modeled as two independent
uniform (0, 1) distributions. The EST read count of the
exon inclusion isoform in each tissue was assumed to
follow a binomial distribution. A Bayesian posterior
probability was calculated to assess whether the exon in-
clusion levels of an exon differed between two tissues.
Similar approaches were later used to identify
cancer-speciﬁc alternative splicing events (11,12). These
studies pioneered the use of RNA sequence count data
for quantitative splicing analysis. However, due to the
low throughput of EST sequencing, EST-based analysis
of differential alternative splicing has limited capacity
and high noise (13).
Recently, with the advent of the high-throughput
RNA sequencing technology (RNA-Seq), it has become
feasible to generate hundreds of millions of short
RNA-Seq reads on any RNA sample of interest (14). This
technology enables genome-wide quantitative analyses of
RNA alternative splicing (3,4). Pan and colleagues
demonstrated that if the RNA-Seq coverage of an alterna-
tively spliced cassette exon reaches at least 20 reads for one
of its exon–exon junctions, the exon inclusion levels
estimated by RNA-Seq strongly correlate with splicing
microarray measurements (4). Other studies comparing
RNA-Seq data to RT–PCR data reached similar conclu-
sions (15–17). Thus, by analyzing and comparing deep
RNA-Seq data from different biological conditions, one
can identify exons with changes in exon inclusion levels
onagenomescale.FromtheRNAsequencecountdata,dif-
ferentialalternativesplicingeventsarecommonlyidentiﬁed
by testing the equality of transcript isoform ratios between
samples (11,15,16,18–20). Various methods have been used
toassessthestatisticalsigniﬁcanceofsuchdifferentialalter-
native splicing events, including Fisher exact test of
isoform-speciﬁc read counts (15,19,20), and Bayesian
approachesthatmodelreadcountsassampledfromaprob-
abilistic mixture of distinct isoforms (11,16,21).
In this article, we introduce MATS (multivariate
analysis of transcript splicing), a Bayesian statistical
framework for ﬂexible hypothesis testing of differential
alternative splicing patterns on RNA-Seq data.
Compared to previous computational methods for detect-
ing differential alternative splicing events from RNA
sequence count data, MATS has several novel features.
First and most importantly, MATS offers the ﬂexibility
to identify differential alternative splicing events that
match a given user-deﬁned pattern. For example, MATS
can calculate the statistical signiﬁcance that the absolute
difference in the exon inclusion levels of an exon between
two conditions exceeds a given threshold (e.g. 10%). This
allows biologists to identify alternative splicing changes
that reach any speciﬁed magnitude. MATS can also be
used to detect exons with the extreme ‘switch-like’ differ-
ential alternative splicing pattern, i.e. exons predominant-
ly included in the transcripts in one condition but
predominantly skipped in another condition. This
switch-like pattern is of considerable biological interest,
because it is a strong indicator of functional alternative
splicing events (3,22). Second, MATS uses a multivariate
uniform distribution as the joint prior for the exon inclu-
sion levels in two conditions. Compared to the independ-
ent uniform priors commonly used by previous methods,
the multivariate uniform prior is more general and better
captures the genome-wide similarity in exon splicing
patterns between biological conditions. Of note, this
prior distribution is motivated by the observation that
between any two conditions there is generally an overall
positive correlation in exon splicing patterns, and only a
small percentage of alternatively spliced exons undergo
differential splicing (see ‘Results’ section). Finally,
MATS employs a Markov chain Monte Carlo (MCMC)
method coupled with a simulation-based adaptive
sampling procedure to calculate the P-value and false dis-
covery rate (FDR) of differential alternative splicing, by
comparing the posterior probability of the observed data
to a set of posterior probabilities simulated from the null
hypothesis. This approach is applicable to almost any type
of null hypotheses of interest. To evaluate the perform-
ance of MATS, we analyzed a deep RNA-Seq data set
with 256 million reads on a human breast cancer cell line
(MDA-MB-231) with ectopic expression of the epithelial-
speciﬁc splicing factor ESRP1 or an empty vector (EV)
control. In this experimental system, the splicing factor
ESRP1 induces large-scale changes in alternative splicing
towards an epithelial-speciﬁc splicing signature (23).
Based on the MATS result, we selected 164 exons that
covered a broad range of FDR values for RT–PCR valid-
ation.ForexonswithaMATSFDRof<10%,weobtained
a high overall RT–PCR validation rate of 86%,
demonstrating that MATS can reliably detect differential
alternative splicing events. Additionally, over the full list
of RT–PCR tested exons, we observed a progressive
decrease in the RT–PCR validation rate with increasing
FDR values, suggesting MATS can yield experimentally
meaningful FDR estimates to help biologists interpret
RNA-Seq predictions and design follow-up experiments.
MATERIALS AND METHODS
Overview of MATS
MATS is a Bayesian statistical framework to detect dif-
ferential alternative splicing events from RNA-Seq data.
For every alternatively spliced cassette exon, MATS
assesses the statistical signiﬁcance of differential alterna-
tive splicing based on a user-deﬁned hypothesis. The
default analysis of MATS is to test whether the difference
in the exon inclusion levels between two samples exceeds a
given user-deﬁned threshold (e.g. 10%). Compared to
existing RNA-Seq analysis methods that test the equality
e61 Nucleic Acids Research, 2012,Vol. 40,No. 8 PAGE 2 OF 13of exon inclusion levels between samples, the MATS test
of splicing difference has three advantages. First, it
provides a rigorous statistical framework for biologists
to identify alternative splicing changes that reach any
speciﬁed magnitude. Second, it improves robustness
against random sampling noise in the RNA-Seq data,
which could cause a minor shift in the estimated isoform
ratio between samples. For exons with high RNA-Seq
read counts such as those from highly expressed genes,
such random noise might introduce false positives to a
test of equality on exon inclusion levels. Third, the
ﬂexible hypothesis formulation also allows testing of
other types of differential alternative splicing behavior
such as the ‘switch-like’ pattern, in which an exon is pre-
dominantly included in the transcripts in one condition
but predominantly skipped in another condition.
The major steps of MATS are illustrated schematically
in Figure 1. First, for each exon MATS uses the counts of
RNA-Seq reads mapped to the exon-exon junctions of its
inclusion or skipping isoform to estimate the exon inclu-
sion levels in two samples (Figure 1A). Second, the exon
inclusion levels of all alternatively spliced cassette exons
are used to construct a multivariate uniform prior that
models the overall similarity in alternative splicing proﬁles
between the two samples (Figure 1B). Third, based on the
multivariate uniform prior and a binomial likelihood
model for the RNA-Seq read counts of the exon inclu-
sion/skipping isoforms, MATS uses a MCMC method
to calculate the Bayesian posterior probability for
splicing difference. Under the default setting, MATS cal-
culates the posterior probability that the change in the
exon inclusion level of a given exon exceeds a given
user-deﬁned threshold (e.g. 10%; Figure 1C). Finally,
MATS calculates a P-value for each exon by comparing
the observed posterior probability (from Step C) with a set
of simulated posterior probabilities from the null hypoth-
esis (Figure 1D). These P-values are then transformed to
FDR values by the Benjamini–Hochberg FDR method
(24). Below we describe the details of the MATS
algorithm.
Estimating exon inclusion levels
We deﬁne the exon inclusion level ( ) of an alternatively
spliced cassette exon as the percentage of ‘exon inclusion’
transcripts that splice from its upstream exon into the
cassette exon then into its downstream exon among all
such ‘exon inclusion’ transcripts plus ‘exon skipping’ tran-
scripts that splice from its upstream exon directly into its
downstream exon (16,17,25). In a RNA-Seq study, for
each exon in a given sample we count the number of
RNA-Seq reads uniquely mapped to its upstream, down-
stream or skipping exon–exon junctions (Figure 1A). The
upstream junction count (UJC) and the downstream
junction count (DJC) reﬂect the abundance of the exon
inclusion isoform, while the skipping junction count (SJC)
reﬂects the abundance of the exon skipping isoform. Let I
and S represent the counts of exon inclusion and skipping
isoforms respectively. Assuming that the read counts
follow a binomial distribution, the maximum likelihood
estimate (MLE) of the exon inclusion level ( )o fa n
exon in a given sample can be calculated as:
^   ¼ I=ðI+SÞ¼
ðUJC+DJCÞ=2
ðUJC+DJCÞ=2+SJC
Calculating the Bayesian posterior probability for
differential alternative splicing
To compare alternative splicing patterns between two
samples, for each exon we deﬁne  1 and  2 as its exon
inclusion levels in sample 1 and 2. Under the default
setting, MATS tests the hypothesis that the difference in
the exon inclusion levels of a given exon between sample 1
and 2 is above a user-deﬁned cutoff c, i.e. j 1    2j > c.
The cutoff c is a user-deﬁned parameter that represents the
extent of splicing change one wishes to identify. For
example, if a researcher is interested in identifying exons
with at least 10% change in exon inclusion levels, the
cutoff c should be set as 10%. The values of  1 and  2
under the null hypothesis (H0) and the alternative hypo-
thesis (H1) of this test are illustrated graphically in
Figure 1. Basic steps of MATS. (A) For each exon MATS uses the
counts of RNA-Seq reads mapped to the exon–exon junctions of its
inclusion or skipping isoform to estimate the exon inclusion levels in
two samples. (B) The exon inclusion levels of all alternatively spliced
cassette exons are used to construct a multivariate uniform prior that
models the overall similarity in alternative splicing proﬁles between the
two samples. (C) Based on the multivariate uniform prior and a
binomial likelihood model for the RNA-Seq read counts of the exon
inclusion/skipping isoforms, MATS uses a Markov chain Monte Carlo
(MCMC) method to calculate the Bayesian posterior probability for
splicing difference. (D) MATS calculates a P-value for each exon by
comparing the observed posterior probability with a set of simulated
posterior probabilities from the null hypothesis, followed by adjustment
for multiple testing to obtain the FDR value.
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lates the posterior probability of j 1    2j > c from the
RNA-Seq counts, i.e. Pðj 1    2j > cjDataÞ. The P-value
and FDR calculation is described in the next section.
To calculate the posterior probability of j 1    2j > c,
we need to deﬁne the prior probability and the likelihood
model. In MATS, the joint prior distribution of  1 and  2
is modeled as a multivariate uniform distribution (Figure
1B), with marginal distributions as uniform (0, 1) and cor-
relation     uniform (0, 1):
Prior : ð 1, 2Þ  MultiVarUniform 0,1,cor ¼
1  
  1
     
    Uniformð0,1Þ
The multivariate uniform distribution was obtained
by applying cumulative standard normal distribution
functions to a random vector that follows a multivariate
normal distribution. Speciﬁcally, ð 1, 2Þ¼ð  ðZ1Þ,
 ðZ2ÞÞ, where Z1 and Z2 are standard normal random
variables Nð0,1Þ with correlation   and   is the cumulative
distribution function of the standard normal distribution.
The obtained multivariate uniform distribution is equiva-
lent to a bivariate distribution with uniform marginals.
We note that our choice of prior distribution in MATS
differs from previous methods which model the priors of
 1 and  2 as two independent uniform distributions
(11,16). This multivariate uniform prior distribution of
 1 and  2 is motivated by the observation that between
any two biological conditions, there is generally an overall
similarity in the genome-wide alternative splicing proﬁles,
and only a small percentage of alternatively spliced exons
undergo differential splicing. Indeed, our analysis of
several RNA-Seq data sets suggests that this multivariate
uniform prior provides a good ﬁt with empirical data
(see ‘Results’ section). In contrast, the commonly used
independent uniform prior distributions assume that the
splicing activities of the same exon in two different
samples are independent, even if these two samples have
the identical cell type and tissue origin. This lacks bio-
logical justiﬁcation and ﬁts empirical data poorly.
In each sample, the exon inclusion isoform count I
follows a binomial distribution with n ¼ I+S and p ¼  ,
where S is the skipping isoform count.
Assume we have a total of N alternatively spliced
cassette exons, for each exon i ¼ 1,:::,N, we denote:
 i1, i2: exon inclusion levels of exon i in sample 1 and 2;
Ii1,Ii2: counts of the exon inclusion isoform of exon i in
sample 1 and 2;
Si1,Si2: counts of the exon skipping isoform of exon i in
sample 1 and 2.
Likelihood : Ii1j i1   Binomial ðni1 ¼ Ii1+Si1,pi1 ¼  i1Þ
Ii2j i2   Binomial ðni2 ¼ Ii2+Si2,pi2 ¼  i2Þ
The posterior probability of differential alternative
splicing for exon i can be calculated as Pi ¼ Pðj i1    i2j
> cjIi1,Ii2,Si1,Si2,I½ i 1,I½ i 2,S½ i 1,S½ i 2Þ, where the counts
of the exon inclusion/skipping isoforms of exon i and all
other alternatively spliced cassette exons (indexed by [ i])
are used to infer the parameter   in the multivariate
uniform prior as well as  i1 and  i2, and c represents
the user-deﬁned threshold for splicing change.
As this posterior probability cannot be calculated with
an analytic solution in closed-form, we adopt a numeric
solution based on the MCMC method. Speciﬁcally, the
posterior probability is calculated by the JAGS program
(Just Another Gibbs Sampler; http://sourceforge.net/
projects/mcmc-jags/). This program estimates the poster-
ior probability Pðj i1    i2j > cjIi1,Ii2,Si1,Si2,I½ i 1,I½ i 2,
S½ i 1,S½ i 2Þ for all exons and the parameter   of the multi-
variate uniform prior. The parameter   is a global param-
eter for all exons, which describes the overall correlation
of the exon inclusion levels of all alternatively spliced
exons between two samples. Therefore, for N exons
there are a total of 2N+1 parameters, including 2N par-
ameters for exon inclusion levels in two samples and the
Figure 2. Null hypotheses in MATS. (A) Under the default setting of MATS, the H1 alternative hypothesis is that the difference in the exon
inclusion levels between two samples is above the user-deﬁned cutoff c (the white area). The H0 null hypothesis is that the difference is below the
user-deﬁned cutoff c (the gray area). (B) MATS can test the extreme ‘switch-like’ differential alternative splicing pattern with a different hypothesis.
The H1 alternative hypothesis is that the exon inclusion level is below a user-deﬁned threshold s in sample 1 and above 1-s in sample 2, or vice versa
(the white area). The H0 null hypothesis is outside the alternative hypothesis region (the gray area).
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along with all the   values, the data of all N exons are
used as the input for the MCMC sampler. We burn in the
MCMC sampler for 2000 iterations, followed by another
10000 iterations to calculate the posterior probabilities.
The posterior probability of a given exon i (denoted as
Pobs
i ) is estimated by the fraction of iterations with
j i1    i2j c among all 10000 iterations (Figure 1C).
Calculating the P-value and FDR for differential
alternative splicing
We use a simulation-based adaptive sampling procedure
to calculate the P-value and FDR for differential alterna-
tive splicing. In theory, P-value comes from the compari-
son of the observed test statistics with statistics from the
null hypothesis. In MATS, when we test j 1    2j > c,w e
consider the null hypothesis that j 1    2j c. We calcu-
late the P-value of each exon by comparing the posterior
probability of the observed data (Pobs
i ) to a set of posterior
probabilities simulated from the null hypothesis. For each
exon, we ﬁnd the maximum likelihood estimate (MLE) of
the constrained  1 and  2 (denoted as ^  c
1 and ^  c
2) from
the binomial distributions with the counts I1,I2,S1 and S2
in two conditions, subject to the constraint that
j 1    2j c. Speciﬁcally,
ð ^  c
1, ^  c
2Þ¼argmax
j 1  2j c
ðI1 log 1+S1 logð1    1Þ+I2 log 2
+S2 logð1    2ÞÞ
The limited-memory Broyden–Fletcher–Goldfarb–
Shanno box-constraints (L-BFGS-B) algorithm is used
to search for the constrained MLE (26,27). Then we
simulate RNA-Seq count data from the constrained
MLE of ^  c
1 and ^  c
2, and calculate the posterior probability
of j 1    2j > c given the simulated data. The P-value of
each exon is calculated by comparing the posterior prob-
ability of differential splicing based on the observed data
to a set of simulated posterior probabilities. The details of
this calculation for a given exon i are summarized below:
(1) Retrieve the estimated global parameter ^   from the
MCMC calculation of posterior probabilities of all
alternatively spliced exons. The value of ^   is ﬁxed in
the P-value calculation.
(2) For exon i, retrieve the observed posterior prob-
ability from the MCMC calculation Pobs
i ¼
Pðj i1    i2j > cjIi1,Ii2,Si1,Si2,I½ i 1,I½ i 2,S½ i 1,S½ i 2Þ.
(3) For exon i, simulate M posterior probabilities from
the constrained MLE of ^  c
i1 and ^  c
i2. For j ¼ 1,:::,M:
i) Simulate data
Ii1jj ^  c
i1   Binomial ðni1 ¼ Ii1+Si1,pi1 ¼ ^  c
i1Þ;
Si1j ¼ ni1   Ii1j
Ii2jj ^  c
i2   Binomial ðni2 ¼ Ii2+Si2,pi2 ¼ ^  c
i2Þ;
Si2j ¼ ni2   Ii2j
ii) Calculate the posterior probability from the simu-
lated data Ii1j,Ii2j,Si1j,Si2j using the MCMC method
as Psim
ij ¼ Pðj i1j    i2jj > cjIi1j,Ii2j,Si1j, Si2j,^  Þ.
iii) Calculate the P-value for exon i by comparing
Pobs
i with the simulated {Psim
ij }a s 1
M
PM
j¼1
IðPobs
i   Psim
ij Þ.
For each exon, the number of M is determined by an
adaptive sampling procedure (see below).
The number of simulations (M) in calculating the
simulated posterior probabilities is determined by an
adaptive sampling procedure. Initially, we aim to reach
a P-value precision of 0.01 by setting M=100. One
hundred simulated posterior probabilities are calculated
for each exon, and the exon’s P-value is generated by
comparing the observed posterior probability to the
simulated ones. A zero or close-to-zero P-value for any
exon indicates that the number of simulations is insufﬁ-
cient for generating a reliable P-value estimate. For all
exons with a P-value of smaller than three times the pre-
cision, the number of simulations is increased by 10-fold in
a new round of simulation, which increases the precision
of the P-value estimate from 0.01 to 0.001. This adaptive
sampling procedure is repeated for multiple rounds.
The default setting of MATS is to repeat this procedure
for at most six rounds to reach the highest P-value preci-
sion of 10
 7, but this parameter can be adjusted by users.
This adaptive sampling procedure enables us to selectively
increase the precision and running time for exons with
signiﬁcant (i.e. small) P-values, thus reducing the overall
running time needed for all exons.
After we obtain the P-values of all exons, we apply
the classic Benjamini–Hochberg method (24) on these
P-values to obtain the FDR values.
Detecting switch-like differential alternative splicing
MATS offers the ﬂexibility for testing different types of
hypotheses on the differential alternative splicing pattern.
An analysis of considerable biological interest is to identify
exons with the extreme ‘switch-like’ differential alter-
native splicing pattern, i.e. ð 1 < s and  2 > 1   sÞ or
ð 1 > 1   s and  2 < sÞ where s is a user-deﬁned param-
eter between 0 and 1/2. For example, if we set s as 1/3, we
test if the exon inclusion level of an exon switches from
less than 1/3 in one sample to more than 2/3 in the other
sample. Such an extreme switch of exon inclusion levels
between conditions is a strong indicator of functional alter-
nativesplicingevents(3,22).Inthe‘switch-like’test,MATS
considers the null hypothesis that the  1 and  2 are outside
of the region deﬁned by ð 1 < s and  2 > 1   sÞ
or ð 1 > 1   s and  2 < sÞ. The values of  1 and  2
under the null hypothesis (H0) and the alternative hypoth-
esis (H1) for the ‘switch-like’ test are illustrated graphically
in Figure 2B. The same MCMC and simulation procedures
for testing j 1    2j > c can be used to calculate the
Bayesian posterior probability, P-value, and FDR for
‘switch-like’ differential alternative splicing.
Exon–exon junction database of human genes
We constructed a database of exon–exon junctions in
human genes using the Ensembl transcript annotations
(release 57) (28). The database includes all known exon–
exon junctions observed in Ensembl transcripts, as well as
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pairwise fusions of exons within genes. In total, the data-
base contains  3.5 million exon–exon junctions. Each
exon–exon junction sequence is 84bp long with 42bp
from the 30-end of the upstream exon and 42bp from
the 50-end of the downstream exon. This exon–exon junc-
tion database is available for download from the MATS
website http://intron.healthcare.uiowa.edu/MATS/.
RNA-Seq analysis of ESRP1 regulated differential
alternative splicing events in the MDA-MB-231 breast
cancer cell line
MDA-MB-231 cells were maintained and retrovirally
transduced by a cDNA encoding the epithelial-speciﬁc
splicing factor ESRP1 or the empty vector (EV) control
as described previously (23,29). Sequencing libraries were
prepared using the mRNA-Seq Sample Prep Kits
(Illumina) according to the manufacturer’s instructions.
Ten micrograms of total RNA was used to prepare
polyA RNA for fragmentation followed by cDNA synthe-
sis with random hexamers and ligation to Illumina
adaptor sequences. The samples underwent an RNA
quality assurance check and were quantiﬁed using an
Agilent 2100 Bioanalyzer, loaded onto ﬂow-cells for cluster
generation, and sequenced on an Illumina Genome
Analyzer II using single-end protocol to generate 76bp
reads (Illumina). The resulting RNA-Seq dataset consisted
of 256 million single-end reads, including 136 million
reads for the ESRP1 sample and 120 million reads for
the EV sample.
During the quality assessment of our 76bp single-end
RNA-Seq data, we found that the ﬁrst two 25bp segments
of these reads had a high mapping rate to the human
genome, while the 3rd 25bp segment had a much lower
mapping rate (data not shown). This is likely due to the
increased sequencing error rate near the 30-end of
the Illumina RNA-Seq reads. Thus, we decided to use
the ﬁrst 50bp of each read for mapping and subsequent
analysis. We mapped RNA-Seq reads to the human
genome (hg19) and the exon–exon junction database,
using the software Bowtie (30) allowing up to 3bp
mismatches. Each mapped exon–exon junction read
required at least 8bp from each side of the exon–exon
junction. We further removed exon–exon junction reads
that mapped to either the human genome (hg19) or
multiple exon–exon junctions. For all identiﬁed alterna-
tively spliced cassette exons, the exon–exon junction
counts were used as the input for MATS.
Illumina Human Body Map 2.0 data on 16 human tissues
We obtained a paired-end RNA-Seq data set from
Illumina, with  80 million read pairs per tissue for 16
human tissues (adipose, adrenal, brain, breast, colon,
heart, kidney, liver, lung, lymph node, ovary, prostate,
skeletal muscle, testes, thyroid and white blood cells).
This data set was referred to as the ‘Human Body Map
2.0’ by Illumina. For each paired-end read (50bp 2), we
mapped each end to the human genome (hg19) and the
exon–exon junction database, using the software Bowtie
(30) allowing up to 3bp mismatches. The ﬁnal mapping
location of the paired-end read was determined by
requiring that the two ends be mapped in the opposite
orientation to the same genomic region, with a
maximum genomic distance of 50kb between the two
ends (to allow introns between the two mapped ends).
RT–PCR validation
Quantitation of alternative splicing was performed using
standard RT–PCR incorporating radiolabeled dCTP or
ﬂuorescently labeled primers, or high-throughput RT–
PCR at the Universite ´ de Sherbrooke as described
(23,31). Since we used MATS to test j 1    2j > 0:1, we
deﬁned a differential alternative splicing event as validated
if the RT–PCR-based exon inclusion levels differed by at
least 10% between the two samples with the direction of
change matching the RNA-Seq prediction.
RESULTS
Multivariate uniform prior in MATS
MATS uses a multivariate uniform distribution to model
the joint prior of exon inclusion levels of alternatively
spliced cassette exons in two samples. This is different
from and more general than the independent uniform
priors used by previous methods (11,16). Note that the
multivariate uniform prior includes the independent
uniform prior model as a special case ( =0). These two
types of prior distributions have distinct underlying as-
sumptions on the alternative splicing patterns of different
biological conditions. Intuitively, the multivariate uniform
prior allows the modeling of similarity in alternative
splicing patterns between two samples (using the correl-
ation parameter  ). In contrast, the independent uniform
priors assume that the global splicing pattern of one
sample is independent of the other sample. To determine
whether the multivariate uniform prior is appropriate and
able to capture the correlation pattern in the data, we
analyzed two RNA-Seq data sets covering diverse tissues
and cell types.
We ﬁrst compared the alternative splicing proﬁles of a
single cell line subject to two different treatments. The
data set came from our deep single-end RNA sequencing
of a human breast cancer cell line (MDA-MB-231) with
ectopic expression of the epithelial-speciﬁc splicing factor
ESRP1 or an empty vector (EV) control (see ‘Materials
and Methods’ section). ESRP1 encodes a master cell-type
speciﬁc regulator of alternative splicing that controls a
global epithelial-speciﬁc splicing network (23,29). In the
MDA-MB-231 cell line, the ectopic expression of ESRP1
drives coordinated switches of ESRP1-regulated exons
towards an epithelial splicing signature (23). This
provides an excellent system for testing algorithms of
alternative splicing analysis. We generated 136 million
single-end reads on the ESRP1 sample and 120 million
single-end reads on the EV sample. We identiﬁed a total
of 18859 alternatively spliced cassette exons in this data
set. Pan and colleagues previously demonstrated that
RNA-Seq can reliably estimate the exon inclusion levels
of alternatively spliced exons, when the sequencing
coverage reaches at least 20 reads for one of the three
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correlation in alternative splicing patterns between these
two samples (ESRP1 and EV), we restricted our analysis
to 12890 alternatively spliced cassette exons with at least
20 reads mapped to one of the three exon-exon junctions
in both samples. We observed a high correlation in
the exon inclusion levels of these exons between the
ESRP1 and EV samples (Pearson correlation r=0.95,
P<2.2e-16; Figure 3A). In contrast, the exon inclusion
levels simulated from two independent uniform priors
had no correlation between the two samples (Pearson
correlation r=0; Figure 3B), contradicting with the
real data.
To assess if the multivariate uniform prior is capable of
modeling the correlation pattern in the data, we used our
MCMC procedure to obtain the estimate of the correl-
ation parameter   on the real ESRP data set. As the
control, we analyzed 10000 simulated data sets using
exon inclusion levels simulated from two independent
uniform priors, in which no correlation existed between
the two samples. For the ESRP data, our MCMC proced-
ure obtained an estimate of   of 0.93, consistent with the
high overall positive correlation observed in the data. In
contrast, the estimates of   on the 10000 simulated data
sets were close to 0, indicating no correlation between the
two samples (Figure 3C). These results suggest that the
multivariate uniform prior model is ﬂexible enough for
both situations, and that the MCMC procedure is
capable of obtaining an estimate of the parameter   that
reﬂects the degree of correlation in the data.
To assess if the pattern observed in the MDA-MB-231
cell line holds true when we compare more distantly
related samples of different tissue origins, we analyzed
the Illumina Human Body Map 2.0 data on 16 human
tissues (see ‘Materials and Methods’ section). We per-
formed pairwise comparisons of alternative splicing
proﬁles of all possible tissue pairs. Between any two
tissues, we observed a high overall correlation in the
estimated exon inclusion levels of alternatively spliced
cassette exons, with the Pearson correlation coefﬁcient
ranging from 0.89 to 0.97 (Supplementary Figure S1).
These data further justify the use of the multivariate
uniform prior, even for the comparison between more
divergent samples representing different tissue types.
Simulation study of MATS
We evaluated the performance of MATS with a simula-
tion study. Speciﬁcally, we generated a simulated
RNA-Seq data set with a mixture of data points repre-
senting non-differentially spliced exons and differentially
spliced exons. The threshold of the exon inclusion level
difference between two samples was set as 10% in our
simulation study (i.e. j 1    2j > 0:1). We generated
data for non-differentially spliced exons by sampling the
exon inclusion level of an exon in sample 1 from a uniform
(0, 1) distribution, and randomly added or subtracted a
small variation drawn from a uniform (0, 0.1) distribution
to obtain the exon inclusion level in sample 2. We
generated data for differentially spliced exons by
sampling the exon inclusion level of an exon in sample 1
from a uniform (0, 1) distribution, and randomly added or
subtracted a large variation drawn from a uniform (0.1, 1)
distribution to obtain the exon inclusion level in sample 2.
For all simulated exons, if the variation added to or sub-
tracted from the exon inclusion level in sample 1 caused
the exon inclusion level in sample 2 to be above 1 or below
0, the sampling step for the variation was repeated until
the exon inclusion level in sample 2 was within the [0,1]
range. In the simulated data, we generated a total of 5000
data points in which 95% represented non-differentially
spliced exons and 5% represented differentially spliced
exons (Figure 4A). After the exon inclusion levels were
simulated for 5000 exons, we generated 5 simulated data
sets, by setting the total inclusion+skipping isoform
junction counts per exon and sample as 100, 200, 500,
Figure 3. The multivariate uniform prior can model the between-sample correlation pattern in the RNA-Seq data. (A) The scatter plot of the
estimated exon inclusion levels of 12890 alternatively spliced cassette exons in the ESRP1 and EV samples. Only exons with at least 20 reads mapped
to one of the three exon–exon junctions in both samples are included in the plot. (B) The scatter plot of the exon inclusion levels in two samples
simulated from two independent uniform priors. In (A and B), the two red lines deﬁne the area where j 1    2j 0:1. (C) The MCMC estimate of
the correlation parameter   can capture the correlation pattern in the data. For the ESRP data, ^   is 0.93 (the red vertical line). For the 10000
simulated data sets from independent uniform priors, ^   is distributed close to zero.
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of an exon in a sample was then calculated as the product
of its simulated exon inclusion level and the total junction
count. After the simulation data sets were generated, we
used MATS to calculate the P-value and FDR of each
exon, and compared the estimated FDRs to the true
FDRs. As shown in Figure 4B–F, although the estimated
FDRs were generally more conservative (i.e. with higher
values) than the true FDRs, the overall curve of the
estimated FDR followed the trend of the true FDR
curve, especially for exons ranked by MATS among the
top 250 (i.e. the number of true positives in our simulated
Figure 4. Simulation study of MATS. (A) Simulated exon inclusion levels of 5000 exons in two samples. A total of 95% of the data points are
simulated from the null hypothesis (j 1    2j 0:1) and 5% are simulated from the alternative hypothesis (j 1    2j > 0:1). (B–F) MATS FDR
estimates on simulated data with the exon inclusion levels from (A) and the total junction count per exon and sample as 100 (B), 200 (C), 500 (D),
1000 (E) and 2000 (F). In each panel, exons are rank sorted by MATS FDR estimates in ascending order. The zoomed-in ﬁgure shows the FDR
estimates of the top 250 exons by MATS.
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FDR when the MATS rank of differential alternative
splicing approached 250, consistent with the total
number of true positives in the simulated data.
Moreover, the number of exons with MATS FDR value
of close to 0 increased progressively with increasing
simulated junction counts (see the zoomed-in ﬁgures of
Figure 4B–F), reﬂecting the inﬂuence of RNA-Seq depth
on the sensitivity of detecting differential alternative
splicing events. We note that non-differentially spliced
exons constitute 95% of the simulated data points. For
such exons, the correct FDR estimates should be high
FDR values.
To further evaluate the performance of the MATS algo-
rithm especially the beneﬁt of the correlation parameter  ,
we conducted another simulation study to compare
MATS with a simpliﬁed MATS Bayesian model in
which   is ﬁxed at 0 (i.e. independent prior), as well as
the Fisher exact test. As in the previous simulation study,
we generated 5000 data points in which 95% represented
non-differentially spliced exons and 5% represented dif-
ferentially spliced exons. To mimic the overall distribution
of junction counts in real data sets, for each simulated
exon its total junction counts (i.e. inclusion+skipping
isoform junction counts) in sample 1 and 2 respectively
were randomly sampled from the MDA-MB-231 ESRP1
data set by taking the counts of a randomly selected alter-
natively spliced cassette exon in the ESRP1 and EV
samples. For each of the three methods tested, we
calculated the true positive rate and false positive rate
under sliding P-value cutoffs from 0 to 1. We then
generated the receiver operating characteristic (ROC)
curve for each method as the true positive rate versus
false positive rate plot, and calculated the area under
curve (AUC) for each method (Figure 5). MATS had
the highest AUC of 0.96, signiﬁcantly better than the
simpliﬁed MATS Bayesian model with   ¼ 0 (AUC=
0.88, DeLong’s Test P=6.8e-8). MATS also signiﬁcantly
outperformed the Fisher exact test (AUC=0.90,
DeLong’s Test P<2.2e-16). Additionally, we note that
even the simpliﬁed MATS Bayesian model (with   ¼ 0)
outperformed the Fisher exact test in the most critical
area of the ROC curve where the false positive rate was
low (Figure 5). This indicates that by testing for difference
(with a threshold) instead of equality, the test statistics is
better at separating true positives from false positives.
MATS analysis of ESRP1-regulated differential
alternative splicing
To evaluate the performance of MATS on a real data set,
we used MATS to detect ESRP1-regulated differential al-
ternative splicing events using our RNA-Seq data on the
MDA-MB-231 cell line with ectopic expression of ESRP1
or an empty vector (EV) control. For each of the 18859
alternatively spliced cassette exons (deﬁned as exons with
at least one inclusion read and one skipping read in these
two samples), we calculated the Bayesian posterior prob-
ability, P-value and FDR for j 1    2j > 0:1. Among 240
exons with MATS FDR of <10%, all (100%) had poster-
ior probability of >0.85, including 239 (99.6%) and 234
(97.5%) with posterior probability of >0.9 and >0.95 re-
spectively. Figure 6 illustrates a differentially spliced exon
(exon 7 of SPNS1) identiﬁed by MATS. Based on the
RNA-Seq read counts we estimated an exon inclusion
level of 77% in the EV sample and 27% in the ESRP1
sample, with a FDR value of 4.6e-4 (Figure 6A). These
predictions matched RT-PCR results of SPNS1 exon 7
splicing in these two samples (Figure 6B).
To assess the overall accuracy of our FDR estimates, we
selected 164 exons covering a broad range of MATS FDR
values (Supplementary Table S1) and tested their splicing
patterns by RT–PCR. Of all the exons tested by RT–PCR,
111 exons had at least 10% difference in the exon inclu-
sion levels between the two samples with the direction of
change matching the RNA-Seq predictions. This yielded
an overall validation rate of 68%. To assess whether the
validation rate correlated with MATS FDR estimates,
we divided the full list of 164 exons into four cohorts ac-
cording to the estimated FDR values, and calculated the
RT–PCR validation rate for each cohort. We observed a
progressive decrease in the RT–PCR validation rate for
cohorts with increasing FDR values (Figure 7). The ﬁrst
cohort had 92 exons with FDR estimates between 0 to
10%. In this cohort, 79 exons were validated by
RT–PCR as differentially spliced, yielding a high valid-
ation rate of 86%. The second, third and fourth cohorts
corresponded to exons with FDR estimates between 10%
and 30%, between 30% and 60%, and between 60% and
100%. These three cohorts had RT–PCR validation rates
of 73%, 55% and 36%, respectively (Figure 7). These
results indicate that MATS can generate experimentally
meaningful FDR estimates to help biologists with the in-
terpretation of RNA-Seq predictions and the design of
follow-up experiments. There was a sharp increase in the
estimated FDR value after the initial list of top 240–406
exons (Figure 7), with  98% of the exons having a FDR
Figure 5. Simulation study to compare MATS, a simpliﬁed MATS
Bayesian model in which   is ﬁxed at 0 (i.e. independent prior), and
the Fisher exact test. MATS signiﬁcantly outperforms the other two
methods based on the AUC of the ROC curve (i.e. the true positive
rate versus false positive rate plot).
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tribution in the simulation study (Figure 4), probably re-
ﬂecting the number of ESRP1-regulated exons in the
human genome as well as the percentage of which that
can be detected at the current RNA-Seq depth. Of note,
among the 164 exons tested by RT–PCR, 17 had a MATS
FDR of 100%. Only 1 of the 17 exons had more than 10%
change in the RT–PCR estimated exon inclusion levels
with the direction of change matching the RNA-Seq pre-
diction, yielding a low validation rate of only 6% that
closely matched the estimated FDR. This indicates that
MATS can provide reliable FDR estimates for the full
range of possible FDR values.
Since our exon–exon junction database includes all
known exon-exon junctions observed in Ensembl tran-
scripts, as well as hypothetical exon–exon junctions
obtained by all possible pairwise fusions of exons within
genes, we can detect and analyze novel exon skipping
events not supported by existing transcript annotations.
This is important considering the prevalence of tissue-
and condition-speciﬁc alternative splicing (32). Of all
18859 alternatively spliced cassette exons, 5373 represent
known events and 13486 represent novel events. Of the
240 signiﬁcant events with MATS FDR<10%, 140 repre-
sent known events while 100 represent novel events. The
percentage of events called as differentially spliced is sig-
niﬁcantly higher for known events (2.6%; 140/5373) than
for novel events (0.7%; 100/13486). Interestingly, of the 92
RT–PCR tested cassette exons with FDR<10%, the RT–
PCR validation rate of differential alternative splicing is
higher for novel events (98%; 43/44) than for known
events (75%; 36/48).
The MATS algorithm can be naturally extended to
other types of alternative splicing events such as alterna-
tive 50 or 30 splice sites and mutually exclusive exon usage.
In the analysis of alternative 50 or 30 splice sites, the counts
of junction reads that uniquely support the two competing
splice sites can serve as the input for MATS. These counts
can be used to estimate the ‘inclusion level’ of any speciﬁc
splice site. All subsequent analysis steps are identical to
the analysis of differential exon skipping. To illustrate
this, we applied MATS to 1571 alternative 50 splice site
events and 2383 alternative 30 splice site events in the
ESRP1 data set. With a FDR cutoff of 5%, 13 events (9
alternative 50 splice sites and 4 alternative 30 splice sites)
were identiﬁed to undergo signiﬁcant differential splicing
(>10% change) between the ESRP1 and EV samples. The
small number of detected differential alternative 50 or 30
splice sites is consistent with an early study using the
Affymetrix exon 1.0 array (33). One possible explanation
is that ESRP1 regulates a small number of such events in
the transcriptome. Nonetheless, we tested ﬁve events by
RT–PCR, of which three were validated to have at least
10% change in splice site inclusion level (Supplementary
Table S2). Supplementary Figure S2 shows the example of
a validated differential alternative 5’ splice site event in
exon 4 of HNRNPH3.
MATS analysis of switch-like alternative splicing between
brain and 15 other tissues
MATS has the ﬂexibility to detect exons with the extreme
‘switch-like’ differential alternative splicing pattern
Figure 6. RNA-Seq and RT–PCR analysis of SPNS1 exon 7 splicing. (A) RNA-Seq junction counts and MATS result of SPNS1 exon 7 in the EV
and ESRP1 samples. (B) RT–PCR result of SPNS1 exon 7 in the EV and ESRP1 samples.
Figure 7. RT–PCR validation of 164 exons covering a broad range of
MATS FDR values. All exons analyzed by MATS are rank sorted by
FDR estimates (y-axis) in ascending order. The 164 exons tested by
RT–PCR are divided into four non-overlapping cohorts according to
the FDR estimates. The validation rate for each cohort is shown.
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function, we used MATS to detect switch-like differential
alternative splicing events between the brain and each of
the 15 other tissues in the Illumina Human Body Map 2.0
data set. For each pairwise comparison, we tested if the
exon inclusion level of an exon switches from less than 1/3
in one tissue to more than 2/3 in the other tissue (i.e.
ð 1 < 1=3 and  2 > 2=3Þ or ð 1 > 2=3 and  2 < 1=3Þ.
With a FDR cutoff of <50%, a total of 229 exons were
identiﬁed to have the switch-like differential alternative
splicing pattern between the brain and at least one other
tissue. Prior studies have revealed sequence features of
such ‘tissue-switched’ cassette exons characteristic of func-
tional alternative splicing events (3,22). A unique feature
of tissue-switched exons is that they are much more likely
to be exact multiples of 3nt in length, thus alternative
splicing adds or removes a modular peptide segment of
the ﬁnal protein product while preserving the downstream
open reading frame (i.e. ‘frame-preserving’, as opposed
to ‘frame-switching’ for exons not exact multiples of 3nt
in length). Consistent with these ﬁndings, of the 229
switch-like exons detected by MATS between brain and
15 other tissues, 70% are frame-preserving, compared to
42% for other alternatively spliced cassette exons without
switch-like differential alternative splicing (P=0; see
Supplementary Figure S3).
DISCUSSION
We present MATS, a new method to detect differential
alternative splicing events from RNA-Seq data. A major
advantage of MATS over existing methods is that it allows
ﬂexible hypothesis testing of differential alternative
splicing patterns. Most of the published work attempted
to identify differential alternative splicing events by testing
the equality of the exon inclusion levels between samples
(11,15,16,18–20). Some also applied a secondary ﬁlter
(without statistical testing) on the change in the estimated
exon inclusion levels (20). MATS provides a Bayesian
statistical framework to directly test the hypothesis and
evaluate the statistical signiﬁcance that the absolute dif-
ference in exon inclusion levels between two samples
exceeds any user-deﬁned threshold. This allows research-
ers to select the magnitude of splicing changes suitable
for speciﬁc research goals in a rigorous statistical setting.
We assessed the performance of MATS using simulated
data and real RNA-Seq data sets. In the RNA-Seq
analysis of ESRP1 regulated alternative splicing, we
obtained a high RT–PCR validation rate of 86% for can-
didate exons with MATS FDR <10%. Additionally, over
the full list of RT–PCR tested exons, the MATS FDR
estimates matched well with the experimental validation
rate (Figure 7). The MATS framework is also applicable
to other null hypotheses of interest. For example,
MATS can be used to test the hypothesis that an exon
exhibits the extreme ‘switch-like’ differential alternative
splicing pattern.
A novel feature of MATS is the multivariate uniform
prior that models the between-sample correlation in exon
splicing patterns. In both the ESRP data and the Human
Body Map 2.0 data, the degree of correlation between
samples is high, resulting in a high estimated value of
the correlation parameter   for the multivariate prior
model. The high between-sample correlation observed in
real RNA-Seq data is consistent with the mechanism of
splicing regulation in eukaryotic cells. Splicing is a
complex process mediated by extensive interactions
among cis regulatory elements and trans acting regulators
(34). Most splicing regulators may control the splicing of
up to several hundred exons via sequence-speciﬁc protein–
RNA interactions (35). Perturbing a speciﬁc component of
the splicing regulatory pathway usually changes the
splicing activity of a small subset of alternatively spliced
exons, while the majority of alternatively spliced exons
remain unaffected. We also note that when no correlation
exists in the data (see Figure 3 for the simulated data), the
estimate of   by the MCMC procedure is close to zero.
Taken together, our analysis indicates that the multivari-
ate uniform prior model is ﬂexible enough to accommo-
date different degrees of between-sample correlation
in the RNA-Seq data. Moreover, our simulation study
(Figure 5) indicates that incorporating the correlation par-
ameter   in the MATS model improves the performance
of the algorithm.
The MATS software and documentation as well as
the raw ESRP1 RNA-Seq data are freely available
at http://intron.healthcare.uiowa.edu/MATS/. The scripts
provided online include the core MATS program to cal-
culate the posterior probability, P-value and FDR of dif-
ferential alternative splicing from the input junction
counts, as well as accessory scripts to generate junction
counts and detect alternative splicing events from raw
RNA-Seq data. To facilitate data analysis, we also
provide databases of pre-compiled exon-exon junctions
based on the Ensembl (28) or UCSC Known Genes (36)
annotations. We suggest that MATS can be used either as
a stand-alone software for differential alternative splicing
analysis of RNA-Seq data, or as part of an existing
RNA-Seq analysis pipeline to calculate the statistical sig-
niﬁcance of a user-deﬁned differential splicing pattern
using junction counts generated by other mapping proced-
ures or transcript annotation databases. We note that
a number of recent studies have reported biases in
RNA-Seq data such as the non-uniform distribution of
RNA-Seq reads along mRNA transcripts, and have
proposed methods to adjust raw RNA-Seq read counts
by correcting for such biases (18,37–41). Additionally, it
has been demonstrated that in paired-end RNA-Seq, the
distribution of insert size between the two ends can be
utilized to improve the assignment of reads to speciﬁc
transcript isoforms (16). Thus, it is possible to use an ap-
propriate method to adjust raw RNA-Seq read counts and
reﬁne the counts of isoform-speciﬁc junctions, prior to the
hypothesis testing of differential alternative splicing by
MATS. It should also be noted that although the
analysis in this manuscript is mostly focused on exon
skipping events (i.e. differential inclusion/skipping of an
entire exon), exon skipping is only one subtype of alter-
native splicing events. The MATS algorithm can be
readily applied to junction counts generated for other
types of alternative splicing events, as illustrated for
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(Supplementary Figure S2).
MATS currently performs two-group comparison of
two samples, with one sample per group without
within-group replicates. This is the typical experimental
setup in most published RNA-Seq studies of alternative
splicing including studies of splicing regulators (16,20,42),
largely due to the high cost of RNA-Seq to achieve sufﬁ-
cient depth for splicing analysis. However, as the cost of
high-throughput sequencing continues to decline, we an-
ticipate that it will soon become feasible and common for
researchers to incorporate biological replicates in
RNA-Seq studies of alternative splicing (43). Medical re-
searchers may soon be able to generate RNA-Seq data
across a large number of healthy and diseased specimens,
with the depth sufﬁcient for quantifying splicing in each
individual sample. Thus, an important future direction is
to extend the statistical framework to incorporate the use
of RNA-Seq replicates in detecting differential alternative
splicing.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures S1–S3 and Supplementary Tables
S1–S2.
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